Yupeng Zhang

Jan 12, 2025 | mdpi.com | Zhe Liu |Fengxu Xiao |Yupeng Zhang |Jiawei Lu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 28, 2024 | nature.com | Yupeng Zhang |Zhen Xing |Aijun Deng

Deep learning techniques were used in ophthalmology to develop artificial intelligence (AI) models for predicting the short-term effectiveness of anti-VEGF therapy in patients with macular edema secondary to branch retinal vein occlusion (BRVO-ME). 180 BRVO-ME patients underwent pre-treatment FFA scans. After 3 months of ranibizumab injections, CMT measurements were taken at baseline and 1-month intervals. Patients were categorized into good and poor prognosis groups based on macular edema at the 4th month follow-up. FFA-Net, a VGG-based classification network, was trained using FFA images from both groups. Class activation heat maps highlighted important locations. Benchmark models (DesNet-201, MobileNet-V3, ResNet-152, MansNet-75) were compared for training results. Performance metrics included accuracy, sensitivity, specificity, F1 score, and ROC curves. FFA-Net predicted BRVO-ME treatment effect with an accuracy of 88.63% and an F1 score of 0.89, with a sensitivity and specificity of 79.40% and 71.34%, respectively.The AUC of the ROC curve for the FFA-Net model was 0.71. The use of FFA based on deep learning technology has feasibility in predicting the treatment effect of BRVO-ME. The FFA-Net model constructed with the VGG model as the main body has good results in predicting the treatment effect of BRVO-ME. The typing of BRVO in FFA may be an important factor affecting the prognosis.

Aug 7, 2024 | arxiv.org | Yupeng Zhang

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Jun 26, 2024 | onlinelibrary.wiley.com | Xiao Han |Yupeng Zhang |Yin Feng Li

1 INTRODUCTION Breast cancer (BC) is the second leading cause of death among all tumours in women, and ER-positive BC accounts for approximately 70% of BC patients.1 Chemotherapy combined with endocrine therapy is an effective treatment for BC. However, drug resistance is a major obstacle in clinical treatment. With the progression of drug resistance, the patterns of surface receptors2 are changed, and the metabolic balance1 is disrupted in tumour cells.

Aug 13, 2023 | dovepress.com | Xiaohong Yu |Yupeng Zhang |Xiaoyang Chen |Sanmei Zhuang

BackgroundEpstein-Barr virus (EBV) is a human herpesvirus that primarily infects B lymphocytes. It is classified as human herpesvirus type 4 and is globally prevalent. EBV infection can lead to a range of diseases, including both neoplastic (cancerous) and non-neoplastic (non-cancerous) conditions.